RAPIFEN

This brand name is authorized in Austria, Brazil, Finland, France, Hong Kong SAR China, Ireland, Netherlands, New Zealand, Singapore, South Africa, Tunisia, UK.

Active ingredients

The drug RAPIFEN contains one active pharmaceutical ingredient (API):

1	Alfentanil UNII 11S92G0TIW - ALFENTANIL HYDROCHLORIDE
	Alfentanil is a short-acting, synthetic, agonist at mu opioid receptors, used for anaesthesia in surgery.
	Read more about Alfentanil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Rapifen 500 micrograms/ml solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01AH02	Alfentanil	N Nervous system → N01 Anesthetics → N01A Anesthetics, general → N01AH Opioid anesthetics
Discover more medicines within N01AH02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501321050030217
FI	Lääkealan turvallisuus- ja kehittämiskeskus	192313, 475916
FR	Base de données publique des médicaments	63670722, 68622560
GB	Medicines & Healthcare Products Regulatory Agency	44007, 44012, 44106
HK	Department of Health Drug Office	23819
NL	Z-Index G-Standaard	12372153, 14333988
NL	Z-Index G-Standaard, PRK	18554, 18562
NZ	Medicines and Medical Devices Safety Authority	3856
SG	Health Sciences Authority	04326P
TN	Direction de la Pharmacie et du Médicament	23693041H, 5743061H
ZA	Health Products Regulatory Authority	Q/2.7/0327